Eisai and Meiji enter into agreement for Parkinson’s disease drug in Asian countries

This article was originally published here

Eisai and Meiji Seika Pharma have entered into a license agreement for the commercialization of safinamide for Parkinson’s disease treatment in Japan and Asia.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply